According to filings with the U.S. Securities and Exchange Commission, Almanac Health is raised $10 Million in new Angel/Seed funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Almanac Health
Almanac Health is a clinical AI platform that brings specialist-grade knowledge to clinicians at the point of care, providing evidence-based clinical decision support across medical specialties, free from pharmaceutical advertising, and governed by institutional controls. The platform integrates with existing EHR systems and is clinically validated through peer-reviewed research. Almanac Health was founded by Cyril Zakka, MD, author of one of NEJM AIs most-cited papers on retrieval-augmented generation for clinical medicine, and is backed by F-Prime, General Catalyst, and Lightspeed Venture Partners.

To learn more, visit https://almanac.chat/
Linkedin Page: https://www.linkedin.com/company/almanachealth/

Contact:
Cyril Zakka, Chief Executive Officer
https://www.linkedin.com/in/cyrilzakka/

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.